Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer : a systematic review and meta-analysis of clinical trials
OBJECTIVES: Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has frequently been associated with poor prognosis. We conducted a meta-analysis of published randomized controlled trials to evaluate multi-kinase inhibitors' efficacy and safety profile treatment.
METHODS: A comprehensive search was conducted using PubMed, Embase, Cochrane, and Medline databases. The quality of literature and trial risk of bias was assessed using the Cochrane risk of bias tool, while the results of progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated using RevMan5.3 software.
RESULTS: Treatment with MKIs significantly improved PFS and OS, but AEs were significantly higher than those in the control group (P < 0.01). The studies demonstrated the median PFS (HR 0.30, 95% CI: 0.18-0.50, P < 0.00001) and OS (HR 0.70, 95% CI: 0.57-0.88, P = 0.002) in RAI-rDTC patients treated with MKIs, and the median PFS of papillary thyroid carcinoma (HR0.28, 95% CI: 0.22-0.37, P < 0.00001) along with follicular thyroid carcinoma (HR0.14, 95%CI 0.09-0.24, P < 0.00001) were extended.
CONCLUSION: MKIs significantly prolonged PFS and OS in patients with RAI-rDTC (P < 0.01). Our recommendation is to use MKIs carefully in patients after evaluating their health status to maximize treatment benefits and minimize adverse effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 22(2022), 9 vom: 14. Sept., Seite 999-1008 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Jingyang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.09.2022 Date Revised 15.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2022.2102000 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34353682X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34353682X | ||
| 003 | DE-627 | ||
| 005 | 20231226020700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2022.2102000 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM34353682X | ||
| 035 | |a (NLM)35833358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Jingyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer |b a systematic review and meta-analysis of clinical trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2022 | ||
| 500 | |a Date Revised 15.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has frequently been associated with poor prognosis. We conducted a meta-analysis of published randomized controlled trials to evaluate multi-kinase inhibitors' efficacy and safety profile treatment | ||
| 520 | |a METHODS: A comprehensive search was conducted using PubMed, Embase, Cochrane, and Medline databases. The quality of literature and trial risk of bias was assessed using the Cochrane risk of bias tool, while the results of progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated using RevMan5.3 software | ||
| 520 | |a RESULTS: Treatment with MKIs significantly improved PFS and OS, but AEs were significantly higher than those in the control group (P < 0.01). The studies demonstrated the median PFS (HR 0.30, 95% CI: 0.18-0.50, P < 0.00001) and OS (HR 0.70, 95% CI: 0.57-0.88, P = 0.002) in RAI-rDTC patients treated with MKIs, and the median PFS of papillary thyroid carcinoma (HR0.28, 95% CI: 0.22-0.37, P < 0.00001) along with follicular thyroid carcinoma (HR0.14, 95%CI 0.09-0.24, P < 0.00001) were extended | ||
| 520 | |a CONCLUSION: MKIs significantly prolonged PFS and OS in patients with RAI-rDTC (P < 0.01). Our recommendation is to use MKIs carefully in patients after evaluating their health status to maximize treatment benefits and minimize adverse effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Multi-kinase inhibitors | |
| 650 | 4 | |a Radioiodine-refractory differentiated thyroid cancer | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a systematic review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 700 | 1 | |a Wang, Menglei |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yuezhong |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jue |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Yazhen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xianlei |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zechen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Shengyou |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 22(2022), 9 vom: 14. Sept., Seite 999-1008 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:9 |g day:14 |g month:09 |g pages:999-1008 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2022.2102000 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 9 |b 14 |c 09 |h 999-1008 | ||